The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

A federal district court ruled in favor of the Health Resources and Services Administration, but raised questions about ...

Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs. Highlights include updates ...